{"product_id":"renovarobio-swot-analysis","title":"Renovaro Biosciences SWOT Analysis","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a clear SWOT framework for analyzing Renovaro Biosciences’s business strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a simple, high-level SWOT template for fast decision-making. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eRenovaro Biosciences SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview below directly mirrors the full SWOT analysis. Upon purchase, this is exactly the document you’ll download.\u003c\/p\u003e\n\u003cp\u003eThere are no alterations or omissions; see the complete breakdown of Renovaro Biosciences.\u003c\/p\u003e\n\u003cp\u003eEvery element showcased in this preview is present in the full version.\u003c\/p\u003e\n\u003cp\u003eYou're seeing the real, finalized SWOT.\u003c\/p\u003e\n\u003cp\u003eAccess the comprehensive analysis instantly upon completing your purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eSWOT Analysis Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eOur glimpse into Renovaro Biosciences’ SWOT reveals key strengths like innovative technology. However, significant weaknesses exist, alongside market opportunities in biotech. We've identified potential threats from competitors and regulatory shifts. This snapshot offers a taste of the strategic landscape.\u003c\/p\u003e\n\u003cp\u003eWant the full story behind the company’s strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocus on Cell, Gene, and Immunotherapy Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRenovaro Biosciences excels in cell, gene, and immunotherapy. This focus targets diseases like cancer and HIV, demonstrating cutting-edge biotechnology. The global cell and gene therapy market is projected to reach $48.7 billion by 2028, offering substantial growth potential. Their innovative approach leverages the body's immune system for disease treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration of AI and Machine Learning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRenovaro Biosciences' use of AI and machine learning is a key strength. This technology helps speed up the discovery of new drugs and improve diagnostic accuracy. By 2024, AI in healthcare was a $14.8 billion market. This approach could lead to better cancer detection and more personalized treatments. The goal is to improve patient outcomes and potentially reduce healthcare costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcquisition of Predictive Oncology Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenovaro's acquisition of Predictive Oncology's assets is a major strength. It grants access to a large biobank and a CLIA-certified lab. This boosts AI-driven drug discovery and diagnostics capabilities. In 2024, the biobank held over 100,000 samples. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRenovaro's strategic collaborations, like the one with Nebul, are a significant strength. These partnerships offer access to cutting-edge resources, including high-performance computing and data analysis capabilities. This can speed up research and development, especially in AI-driven diagnostics. Strategic alliances help to share risks and costs. For instance, the global AI in healthcare market is projected to reach $61.9 billion by 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccess to Specialized Expertise:\u003c\/strong\u003e Partnerships provide access to specialized knowledge.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAccelerated R\u0026amp;D:\u003c\/strong\u003e Collaborations speed up research and development processes.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eShared Resources:\u003c\/strong\u003e Alliances allow sharing of resources.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Expansion:\u003c\/strong\u003e Strategic collaborations can facilitate market entry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline Addressing Significant Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRenovaro Biosciences' strength lies in its pipeline, which focuses on major diseases, including cancer and HIV, tapping into substantial, underserved markets. Their approach targets difficult-to-treat cancers, with the potential for broad application across solid tumors, presenting significant market opportunities. In 2024, the global oncology market was valued at approximately $270 billion, with projections reaching $430 billion by 2028, highlighting the market potential. The HIV treatment market also presents a considerable opportunity. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on large, underserved markets like oncology and HIV.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eTherapies targeting difficult-to-treat cancers.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003ePotential for broad application across various solid tumors.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e Biotech Innovator: AI, Cancer \u0026amp; HIV \u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenovaro's strengths include advanced biotech in cell\/gene therapy, aiming at major diseases such as cancer. AI \u0026amp; machine learning expedite drug discovery and improve diagnostics, vital in the growing AI healthcare sector. Strategic collaborations and asset acquisitions bolster research. Pipeline focuses on underserved markets, presenting considerable opportunities in oncology and HIV treatment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eStrength Area\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003eSupporting Data (2024-2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdvanced Biotech\u003c\/td\u003e\n\u003ctd\u003eCell, gene, immunotherapy focus for diseases.\u003c\/td\u003e\n\u003ctd\u003eCell \u0026amp; gene therapy market: $48.7B by 2028.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI Integration\u003c\/td\u003e\n\u003ctd\u003eUses AI\/ML to boost drug discovery, diagnostics.\u003c\/td\u003e\n\u003ctd\u003eAI in healthcare: $14.8B (2024); $61.9B (2025 est).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Assets \u0026amp; Alliances\u003c\/td\u003e\n\u003ctd\u003eAcquisitions\/partnerships accelerate research.\u003c\/td\u003e\n\u003ctd\u003eBiobank access: over 100,000 samples (2024).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline Focus\u003c\/td\u003e\n\u003ctd\u003eTargets large, underserved markets, like oncology.\u003c\/td\u003e\n\u003ctd\u003eOncology market: $270B (2024); $430B (2028 est).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly Stage Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRenovaro's early-stage pipeline, with most therapies in preclinical or early clinical phases, presents significant weaknesses. This necessitates substantial financial investment and successful trial outcomes. The biotech industry's average time to market for new drugs is 10-15 years. In 2024, Phase 1 trials had a success rate of only 50%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Challenges and Need for Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRenovaro Biosciences faces financial hurdles, requiring consistent funding. Their history shows repeated needs for capital injections. The issuance of preferred shares could dilute shareholder value, raising stability concerns. In Q1 2024, they reported a net loss of $4.5 million, highlighting financial strain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Collaborations and Acquisitions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenovaro's reliance on collaborations and acquisitions poses a weakness. This dependence on external partnerships, particularly for crucial technologies like high-performance computing, could limit its independence. The company's strategic execution may be vulnerable without consistent external support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Issues and Leadership Changes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRenovaro Biosciences' past, particularly its origins as Enochian BioSciences, presents significant weaknesses. The company grapples with historical issues, including serious allegations against a co-founder and concerns regarding data integrity. These past controversies may erode investor confidence and negatively influence market perception. Leadership transitions, while aiming to steer the company forward, haven't fully erased the shadow of its history. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eAllegations of data manipulation and fraud have led to investigations.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eInvestor confidence is fragile due to the company's past scandals.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLeadership changes are an attempt to distance from past controversies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe company's market valuation may be impacted by its history.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStock Price Performance and Nasdaq Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRenovaro Biosciences faces challenges due to its stock performance. The company's stock price has seen a considerable downturn, raising concerns among investors. This decline has led to a notice of non-compliance with Nasdaq's minimum bid price rules. Such issues can hinder Renovaro's ability to secure funding.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eStock Price: Significant decline impacting market perception.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eNasdaq Compliance: Non-compliance with minimum bid price requirements.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eCapital Raising: Low stock price affects ability to raise capital.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eMarket Valuation: Overall market valuation may be negatively affected.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRisks Facing the Biotech Firm: A Critical Look\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRenovaro Biosciences' weaknesses include a high-risk pipeline and financial pressures. Dependence on external partnerships could limit its control. Its history poses reputational and market value risks. Recent stock declines signal investor concerns.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003eEarly-stage; high failure risk\u003c\/td\u003e\n\u003ctd\u003eRequires large investment; slow ROI. Biotech trials (2024): ~50% Phase 1 success.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial\u003c\/td\u003e\n\u003ctd\u003eNeeds funding, previous losses\u003c\/td\u003e\n\u003ctd\u003eDilution risk; Q1 2024 loss = $4.5M; hinders stability.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnerships\u003c\/td\u003e\n\u003ctd\u003eReliance on external technologies\u003c\/td\u003e\n\u003ctd\u003eLimits independence; vulnerability to partners.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistory\u003c\/td\u003e\n\u003ctd\u003ePast controversies \u0026amp; leadership shifts\u003c\/td\u003e\n\u003ctd\u003eErodes investor confidence; may affect valuation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStock\u003c\/td\u003e\n\u003ctd\u003eShare price drop, Nasdaq non-compliance\u003c\/td\u003e\n\u003ctd\u003eImpairs funding; impacts overall market perception.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56069082087808,"sku":"renovarobio-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/renovarobio-swot-analysis.png?v=1749379260","url":"https:\/\/swotanalysistemplates.com\/products\/renovarobio-swot-analysis","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}